Phase II Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers, including Pancreatic Cancer
Summary
The purpose of this phase II study is to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).
General Information
NCT#: NCT03935893
Study ID: 19-004
Trial Phase: Phase II
Trial Sponsor: University of Pittsburgh
Therapies Used in This Trial: Cyclophosphamide, Aldesleukin, Fludarabine, Autologous tumor infiltrating lymphocytes (TIL)
Sign In